Get Our FREE Newsletter

Sign Up

CureVac Drops on Report of Delayed EMA Approval

Spread the love

Investing.com — CureVac NV (NASDAQ:CVAC) tumbled almost 13% after Reuters reported the European Medicines Agency is unlikely to make a decision on its vaccine before August.

German health minister Jens Spahn provided the update on the EMA’s view on the timing of the review on Monday in a call with his regional state counterparts, Reuters said, citing a source at the health ministry familiar with the matter. 

In November, CureVac secured a deal to provide up to 405 million doses of the vaccine to the EU, followed by a memorandum of understanding with Germany for another 20 million doses. Those deals hinge on approval from the EMA. 

CureVac already delayed guidance on its initial testing results.

    

 

This post was originally published on this site